ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for chimeric antigen receptor- T (CAR-T) and other cell-based therapies. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for large scale cell manufacturing services. It manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory useand CAR-TXpress Platform for clinical manufacturing.